186 related articles for article (PubMed ID: 19715673)
1. Vascular PTPs: current developments and challenges for exploitation in Type 2 diabetes-associated vascular dysfunction.
Popov D
Biochem Biophys Res Commun; 2009 Nov; 389(1):1-4. PubMed ID: 19715673
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes.
Tobin JF; Tam S
Curr Opin Drug Discov Devel; 2002 Jul; 5(4):500-12. PubMed ID: 12197308
[TBL] [Abstract][Full Text] [Related]
3. Long-term high glucose concentration influences Akt, ERK1/2, and PTP1B protein expression in human aortic smooth muscle cells.
Popov D; Nemecz M; Dumitrescu M; Georgescu A; Böhmer FD
Biochem Biophys Res Commun; 2009 Oct; 388(1):51-5. PubMed ID: 19647719
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphatases in vessel wall signaling.
Kappert K; Peters KG; Böhmer FD; Ostman A
Cardiovasc Res; 2005 Feb; 65(3):587-98. PubMed ID: 15664385
[TBL] [Abstract][Full Text] [Related]
5. Effects of a supranutritional dose of selenate compared with selenite on insulin sensitivity in type II diabetic dbdb mice.
Müller AS; Most E; Pallauf J
J Anim Physiol Anim Nutr (Berl); 2005; 89(3-6):94-104. PubMed ID: 15787978
[TBL] [Abstract][Full Text] [Related]
6. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity.
Bakker W; Eringa EC; Sipkema P; van Hinsbergh VW
Cell Tissue Res; 2009 Jan; 335(1):165-89. PubMed ID: 18941783
[TBL] [Abstract][Full Text] [Related]
7. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
Nathanson D; Nyström T
Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
[TBL] [Abstract][Full Text] [Related]
8. Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants.
Haase H; Maret W
Biometals; 2005 Aug; 18(4):333-8. PubMed ID: 16158225
[TBL] [Abstract][Full Text] [Related]
9. Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): does a dysfunctional endothelium contribute to the development of type 2 diabetes?
Triggle CR; Howarth A; Cheng ZJ; Ding H
Can J Physiol Pharmacol; 2005; 83(8-9):681-700. PubMed ID: 16333371
[TBL] [Abstract][Full Text] [Related]
10. Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs.
Hooft van Huijsduijnen R; Sauer WH; Bombrun A; Swinnen D
J Med Chem; 2004 Aug; 47(17):4142-6. PubMed ID: 15293983
[No Abstract] [Full Text] [Related]
11. Metal-based anti-diabetic drugs: advances and challenges.
Levina A; Lay PA
Dalton Trans; 2011 Nov; 40(44):11675-86. PubMed ID: 21750828
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus.
Koren S; Fantus IG
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):621-40. PubMed ID: 18054739
[TBL] [Abstract][Full Text] [Related]
13. Endothelial dysfunction in insulin resistance and type 2 diabetes.
Jansson PA
J Intern Med; 2007 Aug; 262(2):173-83. PubMed ID: 17645585
[TBL] [Abstract][Full Text] [Related]
14. Identification of protein tyrosine phosphatases and dual-specificity phosphatases in mammalian spermatozoa and their role in sperm motility and protein tyrosine phosphorylation.
González-Fernández L; Ortega-Ferrusola C; Macias-Garcia B; Salido GM; Peña FJ; Tapia JA
Biol Reprod; 2009 Jun; 80(6):1239-52. PubMed ID: 19211810
[TBL] [Abstract][Full Text] [Related]
15. Redox regulation of protein-tyrosine phosphatases.
den Hertog J; Groen A; van der Wijk T
Arch Biochem Biophys; 2005 Feb; 434(1):11-5. PubMed ID: 15629103
[TBL] [Abstract][Full Text] [Related]
16. Protein tyrosine phosphatases and signalling.
Stoker AW
J Endocrinol; 2005 Apr; 185(1):19-33. PubMed ID: 15817824
[TBL] [Abstract][Full Text] [Related]
17. The vascular trigger of type II diabetes mellitus.
Lammert E
Exp Clin Endocrinol Diabetes; 2008 Sep; 116 Suppl 1():S21-5. PubMed ID: 18777448
[TBL] [Abstract][Full Text] [Related]
18. Chemically chaperoning the actions of insulin.
Hansen PA; Waheed A; Corbett JA
Trends Endocrinol Metab; 2007; 18(1):1-3. PubMed ID: 17116401
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of protein tyrosine phosphatases by amino acid, peptide, and protein hydroperoxides: potential modulation of cell signaling by protein oxidation products.
Gracanin M; Davies MJ
Free Radic Biol Med; 2007 May; 42(10):1543-51. PubMed ID: 17448901
[TBL] [Abstract][Full Text] [Related]
20. MAPK-specific tyrosine phosphatases: new targets for drug discovery?
Barr AJ; Knapp S
Trends Pharmacol Sci; 2006 Oct; 27(10):525-30. PubMed ID: 16919785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
